Abstract: A composition for forming a phase-separated structure contains a block copolymer having a block (b1) consisting of a repeating structure of a styrene unit and a block (b2) consisting of a repeating structure of a methyl methacrylate unit, in which the block (b2) is disposed at least at one terminal portion of the block copolymer, the block copolymer has a structure (e1) represented by General Formula (e1) at least at one main chain terminal, and the structure (e1) is bonded to the main chain terminal of the block (b2) disposed at a terminal portion of the block copolymer. Ree0 represents a hydrocarbon group containing a hetero atom, and Re1 represents a hydrogen atom or a halogen atom.

Abstract: Disclosed is a rare earth complex having a rare earth ion and a phosphine oxide ligand that is coordinated with the rare earth ion and is represented by the following formula (I): wherein R1, R2, R3, R4, R5, and R6 each independently represent an alkyl group which may have a substituent.

Abstract: Disclosed is a cross-coupling reaction method which forms a chemical bond selected from C—N, C—B, C—C, C—O and C—S bonds, the method comprising: preparing an aromatic compound (1) having a leaving group; preparing a compound (2) capable of undergoing a cross-coupling reaction selected from an aromatic amino compound (2-1), a diboronic acid ester or the like (2-2), an aromatic boronic acid or the like (2-3), an aromatic compound (2-4) having a hydroxyl group and an aromatic compound (2-5) having a thiol group; and performing a cross-coupling reaction of the compound (1) with the compound (2) in the presence of a palladium catalyst, a base and a compound (4) having a carbon-carbon double bond or a carbon-carbon triple bond, in the absence of a solvent.

Abstract: A template matching is performed on two fluoroscopic images by using a template image prepared in advance and a position corresponding to a high matching score is listed as a candidate for the position of a marker 29. From two lists of the candidates of the position of the marker 29, the lengths of common vertical lines for all combinations are calculated. Then, the position of the marker 29 is detected based on the matching score and the common vertical line. Then, based on the detected position of the marker 29, an amount of a proton beam to be irradiated to a target is controlled. Therefore, a tracking target can be accurately detected even when the conditions for X-ray fluoroscopy is severe, e.g., a thick object.

Abstract: A processor of a fundus image processing device acquires a fundus image 50 photographed by a fundus image photographing device. The processor acquires blood vessel images 60A and 60B that indicate at least one of an arteriole and a venule in the fundus image 50 by inputting the fundus image 50 into a mathematical model trained by a machine learning algorithm. The processor acquires a blood vessel area that is an area of at least one of the arteriole and the venule in the whole of the blood vessel images 60A and 60B.

Abstract: A treatment planning apparatus 501 or a clinical decision support apparatus 701 calculates a dose distribution, calculates the damage to a normal tissue for a plurality of number of times of radiation irradiation based on the calculated dose distribution, and displays at least one or more calculated damages to the normal tissues on display apparatuses 603 and 703 or outputs the same to an outside of the apparatuses 501 and 701. Accordingly, since effects can be calculated for a plurality of number of times of irradiation, the optimum number of time of irradiation can be presented, and an operator and a doctor can be presented with a suitable decision material of a radiation irradiation planning.

Abstract: The present invention has an objective of providing a novel composition for treating a fibrocartilaginous tissue injury. The present invention provides a composition for treating a fibrocartilaginous tissue injury, which is to be applied to an injured fibrocartilaginous tissue part of a target and which comprises a monovalent metal salt of alginic acid, more preferably a low endotoxin monovalent metal salt of alginic acid.

Abstract: A planar transformer includes: a primary side planar air core coil; a secondary side planar air core coil; a primary side planar core; and a secondary side planar core. The secondary side planar air core coil is arranged so as to be spaced from the primary side planar air core coil in the winding center axis direction of the primary side planar air core coil, the secondary side planar air core coil having a non-facing portion configured not to face the primary side planar air core coil in the winding center axis direction. The primary side planar core and the secondary side planar core are stacked on outer sides of the primary side planar air core coil and the secondary side planar air core coil in the directions of the winding center axes, respectively.

Abstract: The present invention provides an O/W type emulsion having a volume median diameter of not more than 100 nm and containing a compound represented by the formula (1) wherein Xa and Xb are each independently X1, X2 or a 1,4-piperazinediyl group; s is 1 or 2, R4 is an alkyl group having 1-6 carbon atoms, na and nb are each independently 0 or 1, R1a, R1b, R2a and R2b are each independently an alkylene group having 1-6 carbon atoms, Ya and Yb are each independently an ester bond, or the like, and R3a and R3b are each independently a liposoluble vitamin residue or the like.

Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

Abstract: An object of the present invention is to provide an echinomycin derivative that has anti-cancer activity equal to or greater than that of echinomycin, and a production method therefor based on a chemical procedure. Provided are an echinomycin derivative represented by formula (I), and a production method therefor based on a chemical procedure.

Abstract: The present invention pertains to a polycrystalline membrane containing metal nitride particles represented by the general formula MNx (where M is a metal element in which the Fermi energy is in a position higher than ?4.4 eV vs L.V. and x is the range over which a rock salt-type structure can be assumed), in which the crystallite size determined by transmission electron microscopy is 10 nm or less, at least some of the crystallites have rock salt-type structure, and the crystallites exhibit (111) orientation but substantially do not exhibit (100) orientation. The present invention also pertains to a method for manufacturing a polycrystalline membrane, comprising forming, by sputtering, a polycrystalline membrane on a substrate having a temperature of less than 200° C.

Abstract: Provided are: a multilayer structure in which a titanium oxide layer exhibits excellent photocatalytic activity; and a method for producing this multilayer structure. The above-described multilayer structure comprises: a conductive part which contains a metal element A other than Ti, while having electrical conductivity; and a titanium oxide layer which is arranged on the conductive part and contains 1.0% by atom or more of the metal element A.

Abstract: Provided is a composition for suppressing pain which contains a monovalent metal salt of alginic acid, the composition being applied to a nucleus pulposus cavity part to suppress pain at a surgical site and/or a surrounding site thereof which occurs after surgery. Accordingly, a composition is provided, which suppresses pain and/or inflammation at a surgical site and/or a surrounding site thereof which occurs after surgery performed on an intervertebral disc as typified by intervertebral discectomy.

Abstract: A quantum cryptographic key output apparatus includes a semiconductor laser device that repeatedly generates pulsed laser light, an encoder that encodes the pulsed laser light based on a quantum cryptographic key, an optical branching unit that branches the pulsed laser light, and an attenuator that attenuates a light intensity of first pulsed laser light so that the number of photons of the first pulsed laser light has any one of a plurality of candidate values that are values equal to or smaller than 1. Further, the output apparatus includes a light intensity determination unit that determines whether or not a light intensity of a second pulsed laser light is in a predetermined range, and an information output unit that outputs specifying information for specifying the first pulsed laser light corresponding to second pulsed laser light of which the light intensity is not in the predetermined range to an input apparatus.

Abstract: Provided is a functional structure which can suppress functional degradation of a functional material to achieve longer life, which can save resources without complicated replacement operations, and which, used for example as a catalyst, exhibits excellent catalytic activity. The functional structure includes supports each having a porous structure and including a zeolite-type compound, and at least one functional material present in the supports and including a metal element (M), in which each of the supports has channels communicating with one another, the functional material is present at least in the channel of each of the supports, and the metal element (M) having constituted the functional material is partially substituted with an element having constituted the supports.

Abstract: The present invention pertains to a pharmaceutical composition comprising ?-galactosylceramide and/or dendritic cells pulsed with ?-galactosylceramide, said pharmaceutical composition being for preventing and/or treating drug-induced myocardial dysfunction. The present invention also pertains to a pharmaceutical composition comprising ?-galactosylceramide and/or dendritic cells pulsed with ?-galactosylceramide, said pharmaceutical composition being to be administered to a subject, who develops drug-induced myocardial dysfunction or is at a risk of developing the same, before and after administering the drug that is likely causative of the drug-induced myocardial dysfunction.

Abstract: In order to provide an antibody having high therapeutic and prophylactic effects against cancer and the like, three types of mouse monoclonal antibodies were prepared which exhibit high affinities for a human-derived Eva1 protein. Moreover, constant regions of these antibodies were substituted with human-derived constant regions to also prepare chimeric antibodies. Further, these mouse antibodies and chimeric antibodies were found to have high ADCC and/or CDC activities. Furthermore, it was also revealed that administering these antibodies to mice having been subjected to melanoma cell administration suppresses the metastasis and the like of the cells to the lungs.

Abstract: [Problem] The purpose of the present invention is to provide a modified adenovirus having a cytocidal activity on a target cell and high safety. [Solution] The present invention pertains to: a modified adenovirus which comprises an E1A gene, an enhancer sequence having a function of enhancing the expression of the E1A gene, and an AU-rich element introduced into the 3?-untranslated region of a viral gene, which is essentially required for the self-propagation thereof, or a position adjacent to the 3?-untranslated region, or a modified adenovirus which comprises an E1A gene and an enhancer sequence having a function of enhancing the expression of the E1A gene and cannot express normal E4orf6 protein, wherein the distance between the 5?-terminus of the E1A gene and the terminus of the enhancer sequence is 1500-4500 bp; and a medicine comprising the same.

Abstract: An image processor applies computation processing to a plurality of CT images formed by irradiation of radiation of a plurality of energy levels to acquire monochromatic CT images. The image processor acquires a first energy level CT image formed by irradiation of first energy level radiation and a second energy level CT image formed by irradiation of second energy level radiation, applies a plurality of weighted computations to the first and second energy level CT images to compute a plurality of monochromatic CT images as a result of the weighted computations, segments a surrounding region of a highly-absorbent material circumferentially into a plurality of regions of interest having a predetermined area and calculates a standard deviation of the surrounding region by using a mean value of image data of each region of interest, for each monochromatic CT image, and selects a monochromatic CT image with a small standard deviation.